Prognostic and predictive significance of MSI in stages II/III colon cancer
- PMID: 24944470
- PMCID: PMC4051919
- DOI: 10.3748/wjg.v20.i22.6809
Prognostic and predictive significance of MSI in stages II/III colon cancer
Abstract
In colon cancer, classic disease staging remains the key prognosis and treatment determinant. Although adjuvant chemotherapy has an established role in stage III colon cancer patients, in stage II it is still a subject of controversy due to its restriction to a small subgroup of patients with high-risk histopathologic features. Patients with stage II tumors form a highly heterogeneous group, with five-year relative overall survival rates ranging from 87.5% (IIA) to 58.4% (IIC). Identifying those for whom adjuvant chemotherapy would be appropriate and necessary has been challenging, and prognostic markers which could serve in the selection of patients more likely to recur or benefit from adjuvant chemotherapy are eagerly needed. The stronger candidate in this category seems to be microsatellite instability (MSI). The recently reported European Society for Medical Oncology guidelines suggest that MSI should be evaluated in stage II colorectal cancer patients in order to contribute in treatment decision-making regarding chemotherapy administration. The hypothetical predictive role of MSI regarding its response to 5-fluorouracil-based adjuvant chemotherapy has proven a much more difficult issue to address. Almost every possible relation between MSI and chemotherapy outcome has been described in the adjuvant colon cancer setting in the international literature, and the matter is far from being settled. In this current report we critically evaluate the prognostic and predictive impact of MSI status in patients with stage II and stage III colon cancer patients.
Keywords: Colon cancer; Microsatellite instability; Predictive; Prognostic; Stage II; Stage III.
Similar articles
-
Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists.Cancer Rep (Hoboken). 2021 Feb;4(1):e1297. doi: 10.1002/cnr2.1297. Epub 2020 Oct 8. Cancer Rep (Hoboken). 2021. PMID: 33030308 Free PMC article.
-
The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.J Surg Oncol. 2018 Dec;118(8):1311-1317. doi: 10.1002/jso.25275. Epub 2018 Nov 6. J Surg Oncol. 2018. PMID: 30399198
-
Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.Arch Surg. 2009 Sep;144(9):835-40. doi: 10.1001/archsurg.2009.162. Arch Surg. 2009. PMID: 19797108
-
[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].Bull Cancer. 2019 Feb;106(2):129-136. doi: 10.1016/j.bulcan.2018.10.011. Epub 2018 Dec 4. Bull Cancer. 2019. PMID: 30527814 Review. French.
-
Clinical implications of microsatellite instability in sporadic colon cancers.Curr Opin Oncol. 2009 Jul;21(4):369-73. doi: 10.1097/CCO.0b013e32832c94bd. Curr Opin Oncol. 2009. PMID: 19444104 Free PMC article. Review.
Cited by
-
Enhanced Commendable Sensitivity and Specificity for MSI in Colorectal Cancer by a New PCR-HRM Based 8-Loci MSI Assay.J Clin Lab Anal. 2024 Aug;38(15-16):e25085. doi: 10.1002/jcla.25085. Epub 2024 Aug 12. J Clin Lab Anal. 2024. PMID: 39132875 Free PMC article.
-
Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).Int J Clin Oncol. 2024 Sep;29(9):1284-1292. doi: 10.1007/s10147-024-02565-5. Epub 2024 Jun 4. Int J Clin Oncol. 2024. PMID: 38833114 Free PMC article.
-
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.Cancer Cell. 2023 Jan 9;41(1):196-209.e5. doi: 10.1016/j.ccell.2022.12.003. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584674 Free PMC article.
-
Building personalized treatment plans for early-stage colorectal cancer patients.Oncotarget. 2017 Feb 21;8(8):13805-13817. doi: 10.18632/oncotarget.14638. Oncotarget. 2017. PMID: 28099153 Free PMC article.
-
Evaluation of Fluctuations of BRAF Gene Expression and its Polymorphism at rs1267623 in Colorectal Cancer.Microrna. 2024;13(3):202-210. doi: 10.2174/0122115366286360240625095932. Microrna. 2024. PMID: 39005128
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
-
- Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–2204. - PubMed
-
- André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351. - PubMed
-
- O’Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical